SCHEMBL2117057

SCHEMBL2117057

Cc1ccc(-c2cccs2)cc1NS(=O)(=O)c1cnccc1C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 3/20 0.46
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
ACLY P53396 4/20 0.45
HDAC1 Q13547 7/20 0.42
HDAC2 Q92769 7/20 0.42
HDAC3 O15379 6/20 0.42
CYP2E1 P05181 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2A6 P11509 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2B6 P20813 1/20 0.40
PTGES2 Q9H7Z7 1/20 0.39
TP53 P04637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119666 0.86 GHSR (0.56) GHSRKMT2AALDH1A1KDM4EMEN1
SCHEMBL2117478 0.84 GHSR (0.50) GHSRKMT2AALDH1A1KDM4EMEN1
SCHEMBL2119468 0.81 ALDH1A1 (0.39) GHSRKMT2AALDH1A1KDM4EMEN1
SCHEMBL2119638 0.78 KDM4E (0.51) GHSRKMT2AALDH1A1KDM4EMEN1
SCHEMBL2120109 0.77 SLC40A1 (0.46) GHSRKMT2AALDH1A1KDM4EMEN1
SCHEMBL2119636 0.77 GHSR (0.52) GHSRKMT2AALDH1A1KDM4EMEN1
SCHEMBL2120149 0.77 TRIM24 (0.48) GHSRKMT2AALDH1A1MAPTCYP3A4
SCHEMBL2121413 0.77 GHSR (0.50) GHSRKMT2AALDH1A1KDM4EMEN1
SCHEMBL2117332 0.77 KCNJ1 (0.44) KMT2AMAPTCYP3A4PTGES2TP53
SCHEMBL2119380 0.76 LMNA (0.39) ALDH1A1MAPTHDAC1HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 GHSR 1390/4885KMT2A 290/4885ALDH1A1 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.